Please assess the completion status of the following clinical trial:

Trial Title: Trial of Sunitinib for Refractory Malignant Ascites

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumor malignancy and failure of at least one biologic or cytotoxic regimen, or the inability to receive standard treatment due to performance status (PS\>2).~* Ascites based on paracentesis or CT scan within one month prior to enrollment~* Life expectancy \> 3 months~* Indwelling paracentesis catheters are permitted, paracentesis is permitted at the investigators discretion~* Negative urine pregnancy test for females~* All subjects must agree to use birth control~* All subjects must abstain from eating grapefruit and grapefruit juice. They must tell their physicians about any changes in their medication including over-the-counter and herbal supplements.~Exclusion Criteria:~* History of congestive heart failure~* Creatinine \> 2.0~* Pregnant or nursing~* ALT \> 2.5 times the upper limit of normal~* Blood pressure \> 160/90 (antihypertensives permitted)~* Gastrointestinal or intra-abdominal hemorrhage within the last 6 months~* History of QTc \> 450 milliseconds~* Brain metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx

Based on this trial design, predict the completion outcome and termination type (if applicable).